Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive ...

DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...

DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A copy of the same can be downloaded here. Select Growth primarily targets U.S ...

DexCom plans to keep rolling out key new devices in the next year. The company should continue growing its revenue and installed base. It has a massive worldwide opportunity in the diabetes care ...

DexCom Inc. ( DXCM) reported on Monday that Director, Dr. Jay Skyler, invested over $1 million back into DexCom. This marks the first insider buy for DexCom since March of last year. Skyler added ...

Dexcom CGM use is proven to improve glycemic control 1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring. 3 BURNABY, British ...

A few months before his final high school baseball season, Bryce Frederick had a blood test as part of a routine physical. It came back positive for biomarkers that signal the onset of Type 1 diabetes ...